scholarly journals Cost‐effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia

2020 ◽  
Vol 67 (10) ◽  
Author(s):  
Meghan McCormick ◽  
Erika Friehling ◽  
Ramasubramanian Kalpatthi ◽  
Nalyn Siripong ◽  
Kenneth Smith
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Bacterial Infection ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Levofloxacin Prophylaxis ◽  
Acute Myeloid

scholarly journals Levofloxacin for Antibacterial Prophylaxis in Pediatric Patients With Acute Myeloid Leukemia or Undergoing Hematopoietic Stem Cell Transplantation

2020 ◽  
Vol 25 (7) ◽  
pp. 629-635
Author(s):  
Bianka Patel ◽  
Andrew Noda ◽  
Emily Godbout ◽  
Michael Stevens ◽  
Cady Noda
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Hematopoietic Stem ◽  
Levofloxacin Prophylaxis ◽  
Acute Myeloid

OBJECTIVE This study aimed to evaluate the use of levofloxacin for the prevention of bacterial infections in pediatric patients with acute myeloid leukemia or those undergoing hematopoietic stem cell transplantation. METHODS This study was a single-center, retrospective review designed to assess the frequency of bacteremia with levofloxacin prophylaxis compared with historical controls that used other, clinician-directed antibacterial prophylaxis. The primary outcome of the study was microbiologically documented bacteremia. Secondary outcomes included febrile neutropenia, clinically documented infection, duration of neutropenia, treatment antibiotic exposure days, Clostridioides difficile infection, and infection-related mortality. RESULTS Of the 60 patients included, 24 patients with 32 hospital admissions received levofloxacin and 36 patients with 48 hospital admissions received clinician-directed prophylaxis. There was no difference found in the frequency of bacteremia between levofloxacin and clinician-directed prophylaxis (15.6% vs 10.4%, p = 0.49). There was no difference in the incidence of febrile neutropenia, clinically documented infection, treatment antibiotic exposure days, or 30-day infection-related mortality between the 2 groups. The levofloxacin group had a longer mean duration of neutropenia compared with clinician-directed prophylaxis (26.8 days vs 16.4 days, p = 0.01). CONCLUSIONS There was no difference in bacteremia between levofloxacin prophylaxis and clinician-directed prophylaxis in pediatric patients with acute myeloid leukemia or those undergoing hematopoietic stem cell transplantation. Levofloxacin prophylaxis is an appropriate alternative for the prevention of serious bacterial infections in this patient population, although further studies are needed to confirm these results.

scholarly journals Treatment adherence and abandonment in acute myeloid leukemia in pediatric patients at a low-resource cancer center in India

2019 ◽  
Vol 40 (4) ◽  
pp. 501
Author(s):  
Mikael Segerlantz ◽  
Sudha Sinha ◽  
Gustav Brattström ◽  
Gayatri Palat ◽  
Vineela Rapelli ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Treatment Adherence ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Cancer Center ◽  
Low Resource ◽  
Acute Myeloid

scholarly journals Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0192529 ◽  
Author(s):  
Kelly D. Getz ◽  
Tamara P. Miller ◽  
Alix E. Seif ◽  
Yimei Li ◽  
Yuan-Shung V. Huang ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Newly Diagnosed ◽  
Acute Myeloid

Cup-like Blasts in 2 Pediatric Patients With NPM-1-Positive Acute Myeloid Leukemia

2018 ◽  
Vol 40 (4) ◽  
pp. e237-e238
Author(s):  
Özlem Tüfekçi ◽  
Melek Erdem ◽  
Hale Ören ◽  
Şebnem Yilmaz
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document